Sarah Danson
Department of Medical Oncology
Christie Hospital NHS Trust
Withington
Manchester M20 4BX
UK
Name/email consistency: high
- Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Danson, S., Blackhall, F., Hulse, P., Ranson, M. Drug. Saf (2005)
- Improving outcomes in advanced malignant melanoma: update on systemic therapy. Danson, S., Lorigan, P. Drugs (2005)
- DT-diaphorase: a target for new anticancer drugs. Danson, S., Ward, T.H., Butler, J., Ranson, M. Cancer Treat. Rev. (2004)
- Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. Danson, S., Lorigan, P., Arance, A., Clamp, A., Ranson, M., Hodgetts, J., Lomax, L., Ashcroft, L., Thatcher, N., Middleton, M.R. J. Clin. Oncol. (2003)